title: Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs.
abstract: BACKGROUND
  Cancer cachexia, a catabolic state characterized by weight loss, occurs frequently in patients with terminal-stage neoplastic diseases. Gastrointestinal hormones and cytokines may be associated with anorexia and wasting in cancer cachexia.
  
  
  METHODS
  This study aimed to examine the mechanism of anorexia in cachectic patients through a prospective investigation of plasma cytokines, ghrelin, and leptin in 16 cachectic patients with cancer of the digestive organs and 10 healthy volunteers.
  
  
  RESULTS
  Tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-1 receptor antagonist (IL-1Ra), and ghrelin levels were significantly higher in cachectic cancer patients than in the healthy volunteers, whereas leptin was significantly lower in the cachectic cancer patients. Plasma leptin levels and cytokine levels (TNF-alpha and IL-6) correlated significantly with body mass index (BMI), but plasma ghrelin levels did not correlate with BMI or with the grade of symptoms.
  
  
  CONCLUSIONS
  Neither weight loss nor the grade of symptoms seemed to be directly associated with the increase in ghrelin levels. Hence, it is considered that the increase in ghrelin levels cannot simply be explained by an increase in ghrelin secretion, suggesting that other mechanisms, such as the decreased inactivation of ghrelin, may also play a role. Further studies are needed to clarify the mechanisms of the increase in ghrelin levels. Additionally, the changes in plasma cytokines (TNF-alpha and IL-6) and leptin in cachectic cancer patients suggest that these molecules may be useful markers for the evaluation of cancer cachexia.
authors.affiliation: Department of Surgery, Iwate Medical University, Morioka, Japan.
authors.forename: Masanori
authors.initials: M
authors.lastname: Takahashi
authors.forename: Masanori
authors.initials: M
authors.lastname: Terashima
authors.forename: Akinori
authors.initials: A
authors.lastname: Takagane
authors.forename: Kenichi
authors.initials: K
authors.lastname: Oyama
authors.forename: Hisataka
authors.initials: H
authors.lastname: Fujiwara
authors.forename: Go
authors.initials: G
authors.lastname: Wakabayashi
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D002100:Cachexia / Q000097:blood / Q000209:etiology*; D016022:Case-Control Studies; D015536:Down-Regulation; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000097:blood / Q000150:complications*; D054439:Ghrelin / Q000097:blood*; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D020738:Leptin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D015854:Up-Regulation
chemical_list: D015415:Biomarkers; C515349:GHRL protein, human; D054439:Ghrelin; C507763:IL1RN protein, human; C508600:IL6 protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D015850:Interleukin-6; D020738:Leptin; D014409:Tumor Necrosis Factor-alpha
references.citation: Biochem Biophys Res Commun. 2003 Feb 7;301(2):275-9
references.pmid: 12565855
references.citation: J Clin Endocrinol Metab. 2001 Jan;86(1):162-6
references.pmid: 11231995
references.citation: Clin Cancer Res. 2003 Feb;9(2):774-8
references.pmid: 12576449
references.citation: N Engl J Med. 2002 May 23;346(21):1623-30
references.pmid: 12023994
references.citation: J Mol Med (Berl). 2000;78(10):554-61
references.pmid: 11199328
references.citation: J Clin Endocrinol Metab. 2004 Jun;89(6):2832-6
references.pmid: 15181065
references.citation: Nature. 2000 Oct 19;407(6806):908-13
references.pmid: 11057670
references.citation: Cytokine. 2002 Jul 7;19(1):21-6
references.pmid: 12200109
references.citation: J Clin Endocrinol Metab. 2004 Nov;89(11):5392-6
references.pmid: 15531487
references.citation: Gastroenterology. 2001 Feb;120(2):337-45
references.pmid: 11159873
references.citation: Clin Chem. 2004 Sep;50(9):1511-25
references.pmid: 15265818
references.citation: Nature. 1999 Dec 9;402(6762):656-60
references.pmid: 10604470
references.citation: Cancer. 2006 Feb 15;106(4):966-73
references.pmid: 16411208
references.citation: J Clin Invest. 2004 Jul;114(1):57-66
references.pmid: 15232612
references.citation: Curr Pain Headache Rep. 2001 Jun;5(3):250-6
references.pmid: 11309213
references.citation: Metabolism. 2004 Jan;53(1):84-8
references.pmid: 14681847
references.citation: Semin Oncol. 1998 Apr;25(2 Suppl 6):45-52
references.pmid: 9625383
references.citation: J Clin Endocrinol Metab. 2005 May;90(5):2920-6
references.pmid: 15713718
references.citation: Surg Today. 1996;26(7):467-75
references.pmid: 8840426
references.citation: Nature. 1994 Dec 1;372(6505):425-32
references.pmid: 7984236
references.citation: Support Care Cancer. 1993 Nov;1(6):290-4
references.pmid: 8156245
references.citation: Clin Endocrinol (Oxf). 2002 Jun;56(6):723-33
references.pmid: 12072041
references.citation: Curr Drug Targets Inflamm Allergy. 2002 Sep;1(3):277-89
references.pmid: 14561193
references.citation: Nat Rev Neurosci. 2001 Aug;2(8):551-60
references.pmid: 11483998
references.citation: Cancer. 2003 Mar 1;97(5):1211-6
references.pmid: 12599227
references.citation: Clin Sci (Lond). 1997 Sep;93(3):273-7
references.pmid: 9337643
references.citation: Circulation. 2004 May 11;109(18):2221-6
references.pmid: 15117840